3 of the Best Dividend Stocks to Buy in May 2026

The article highlights AbbVie, Verizon, and Canadian Natural Resources as attractive dividend stocks, with yields of 3.4%, 5.9%, and 3.8%, respectively, alongside low forward P/E multiples of about 14, under 10, and under 14. AbbVie has raised its dividend 33% over five years and grew revenue more than 12% in its latest quarter; Verizon has lifted its payout 13% over five years; Canadian Natural Resources has raised its dividend for 26 straight years at a roughly 20% CAGR. The piece is primarily an opinion-driven dividend-stock recommendation rather than a fresh company-specific catalyst.

Analysis

This reads less like a generic dividend screen and more like a quality-factor trade packaged as income. The common thread is that all three names are using cash generation as a defense against multiple compression, but the market is not paying up for that optionality because each sits in a sector with a lingering narrative overhang: pharma patent cliffs, telecom maturity, and energy cyclicality. That creates a decent setup for total-return investors because the next leg of performance is likely to come from mean reversion in valuation rather than dividend yield alone.

The second-order winner is not just the stocks themselves, but the capital allocator profile behind them. AbbVie’s balance sheet flexibility and Verizon’s asset intensity mean both can sustain shareholder returns even in a slower top-line regime, while Canadian Natural’s long payout record signals discipline that typically outlasts spot commodity volatility. The risk is that investors underestimate how much of the current upside is already tied to a “soft landing” macro: if rates stay higher for longer, the bond-proxy nature of VZ can re-rate lower, and if oil rolls over, CNQ’s yield support weakens quickly even if operations remain intact.

The contrarian point: the crowd may be too focused on headline yield and not enough on payout durability versus reinvestment quality. ABBV is probably the cleanest risk/reward because the market is still discounting post-Humira anxiety despite evidence of successful portfolio replacement; VZ is more of a capital return vehicle than a growth story and needs continued execution on fiber integration to avoid value-trap optics; CNQ is the most macro-sensitive, so the thesis works better as a tactical hedge than a core compounder. The key time horizon divergence is important: ABBV can grind higher over 12-24 months, VZ likely needs several quarters of integration proof, and CNQ is tradable over weeks to months with oil price catalysts driving most of the P/L.

Key Decisions for Investors

• Long ABBV vs. a healthcare basket short on a 6-12 month horizon: best risk/reward among the three because the market still assigns too much terminal-value discount to post-patent durability; target a valuation re-rating rather than just dividend carry.
• Buy VZ only on weakness and size it as an income trade, not a growth trade: use a 3-6 month time frame and cap upside expectations unless fiber integration shows up in subscriber and margin data.
• Use CNQ as a tactical inflation/energy hedge rather than a core holding: hold for 1-3 months around oil strength, but be prepared to trim quickly if crude starts to roll over or geopolitical risk premium fades.
• Pair trade idea: long ABBV / short VZ to express 'quality compounding vs. bond-proxy income' over 6 months; ABBV has more upside from sentiment repair, while VZ remains vulnerable if rates back up.
• If seeking income with asymmetric downside protection, prefer ABBV over VZ and CNQ because its yield is lower but the probability-weighted total return is better; use pullbacks as entry points rather than chasing yield.